ReNeuron Group plc Virtual conference attendance and presentations
April 06 2021 - 1:00AM
RNS Non-Regulatory
TIDMRENE
ReNeuron Group plc
06 April 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Virtual conference attendance and presentations
CEO and CMO to present at Cell & Gene Meeting on the
Mediterranean
CEO to present at the Investing in Cures Summit
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces it will be
presenting at two virtual conferences, the virtual Cell & Gene
Meeting on the Mediterranean ('Meeting on the Med') conference,
which takes place on 6-9 April 2021 and the Investing in Cures
Summit, " Latest Advances from Clinical Trials and Industry
Partnership", on 12-17 April 2021.
The Meeting on the Med conference is organised by the Alliance
for Regenerative Medicine and brings together specialists and
companies in the cell and gene therapy community from across
Europe. It will be delivered virtually and includes a mix of on
demand content that will be released each morning and two
live-stream panels each day. Virtual attendees will have access to
presentations from over 80 companies, virtual exhibit booths and
panel chats.
Richard Beckman, Chief Medical Officer of ReNeuron, will chair a
meeting titled " Gene Therapies for Ophthalmologic Diseases" as
part of the on-demand content available from Tuesday 6 April. The
panel will discuss aspects of the eye and ocular disease that make
it an attractive target for cell and gene therapy, as well as
potential future developments that may occur in the space. CEO,
Olav Hellebø, will also be presenting at the event providing an
overview and highlighting the Company's technical and clinical
achievements over the past 12 months.
For more information and to register for the event, please
visit: https://meetingonthemed.com/
The Investing in Cures Summit, hosted by the Foundation Fighting
Blindness and Retinal Degeneration Fund, is a limited-attendance
summit that engages key stakeholders, key opinion leaders, clinical
trial investigators, and companies advancing promising therapies.
As part of a series of webcasts focused on therapies in development
to address retinal degenerations, Olav Hellebø will host a
presentation focusing on ReNeuron's technologies and business
objectives in the retinal disease space.
No new material will be disclosed at these events and the
presentations will be available on the Company website following
the events: http://www.reneuron.com/investors/presentations/
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. he Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAQFLFXFXLEBBL
(END) Dow Jones Newswires
April 06, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2023 to Apr 2024